Protagonist Therapeutics, Inc【PTGX】Cash flow
Market cap
$5B
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based compensation | 2 | 4 | 7 | 8 | 8 | 16 | 24 | 29 | 38 |
| Cash from operations | -30 | 4 | -50 | -42 | -72 | -108 | -108 | -70 | 184 |
| Capital expenditures | -0 | -1 | -0 | -1 | -0 | -1 | -1 | -1 | -1 |
| Cash from investing | -59 | 16 | 2 | -54 | -91 | -16 | 91 | -39 | -299 |
| Repayments of term debt | - | - | - | - | 11 | - | - | - | - |
| Cash from financing | 106 | 66 | 24 | 46 | 248 | 130 | 19 | 170 | 26 |
| Free cash flow | |||||||||
| FCF margin (%) | - | - | - | - |